Statins in prevention of prostate cancer progression after radical prostatectomy

A detailed review of treatment data from 1,200 patients treated by radical prostatectomy fails to offer any support for the development of a large, prospective trial of the clinical use of statins as adjunct therapy to prevent biochemical progression in men treated surgically for localized prostate cancer. … READ MORE …

Sexual dysfunction among prostate cancer survivors — a new review article

In a newly published article in the Journal of Sexual Medicine, Chung and Brock offer a state of art review of the various types of sexual dysfunction identified among prostate cancer survivors and the management strategies currently available for sexual rehabilitation after treatment. … READ MORE …

5-ARIs and prostate cancer risk: one step forward; one step back

As is so often the case in medicine, data suggesting a positive finding from one study comes out at about the same time as data demonstrating exactly the opposite … and in prostate cancer this occurs all too frequently! … READ MORE …

Overall survival among participants in the Prostate Cancer Prevention Trial

The Prostate Cancer Prevention Trial (PCPT) showed that treatment with finasteride (a 5α-reductase inhibitor) could lower the number of prostate cancers diagnosed in the U.S. each year by about 25 percent. … READ MORE …

One more nail in the coffin for saw palmetto

Extracts of the berries of the saw palmetto plant (Serenoa repens) have long been used as an alternative form of therapy by men with symptoms suggesting lower urinary tract disorders (e.g., difficulty with urination; frequent urination; etc.). However, there is good evidence that such treatment is ineffective. … READ MORE …

No effect of a daily multi-vitamin on risk for prostate cancer in men of 50 or more

Many readers may have seen or heard news reports about a large study that (according to those news reports) implies that taking a daily multi-vitamin may reduce men’s overall, life-time risk for cancer. … READ MORE …

“There’s more to life than death”

We strongly recommend to all our readers a commentary in this week’s New England Journal of Medicine by Drs. Pamela Hartzband and Jerome Groopman. It deals forcefully with distinction between “statistical proof” of the lack of value of PSA testing and the accuracy of that statistical proof as a basis for clinical decision-making. … READ MORE …

Back to the question of whether selenium levels affect prostate cancer risk

A newly published review and meta-analysis in The American Journal of Clinical Nutrition has suggested that biological levels of selenium that fall outside a relatively narrow “normal” range may well be associated with increased risk for prostate cancer. … READ MORE …

Can adhesion receptor blockade lower risk for metastatic prostate cancer?

A group of Finnish researchers have reported the apparent existence of a series of genes that are capable of inhibiting the spread (metastasis) of prostate cancer cells — at least in the laboratory. … READ MORE …

What’s new in the Journal of the Canadian Urologic Association?

The April issue of the Journal of the Canadian Urologic Association offers the interested reader access to the full texts of a small number of topical articles. None of them could be considered “game changing” in terms of current prostate cancer management today … but certainly thought-stimulating. … READ MORE …

Circumcision and prostate cancer risk … correlation is not cause and effect …

A study published recently by researchers based at the University of Washington reported correlation between circumcision and risk for prostate cancer … but it is important to note that (a) they were not claiming to have proven a cause and effect relationship and (b) the supposed increase in risk of 15 percent was an increase in relative (as opposed to absolute) risk. … READ MORE …

Advisory panel does NOT recommend approval of Xgeva for prevention of bone mets

According to an online report in The Washington Post earlier this afternoon, an advisory panel to the U.S. Food and Drug Administration (FDA) has voted 12 to 1 not to recommend the approval of denosumab (Xgeva®) for the prevention of bone metastasis in men with non-metastatic, castrate-resistant prostate cancer. … READ MORE …

Will denosumab gain approval for prevention of onset of metastasis to bone?

The U.S. Food and Drug Administration (FDA) has questioned the value of denosumab (Xgeva®) as an agent capable of delaying the onset of metastatic disease to bone in men with progressive, castration-resistant prostate cancer. … READ MORE …

Still “no sufficient evidence” to support any widespread prostate cancer prevention strategy

A new review of the available literature has concluded that, despite the fact that “prostate cancer is an ideal target for prevention,” there is in fact “no suitable evidence to recommend using any specific nutritional supplement or diet to prevent prostate cancer” at the present time. … READ MORE …

The walnuts are back in vogue (at least with mice)

According to a media release we received yesterday, a new paper in the British Journal of Nutrition suggests that “walnuts may help to prevent prostate cancer risk.” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 832 other followers